the aid library

LIST OPTIONS

Filter

12220

Sort by:

Direction:

Download (94)

View PDF (151)

Countdown to 2015: an analysis of donor funding for prenatal and neonatal health, 2003–2013

Pitt, C.; C. Grollman; M. Martínez-Álvarez et al. BMJ Global Health (2017) C1

Background: In 2015, 5.3 million babies died in the third trimester of pregnancy and first month following birth. Progress in reducing neonatal mortality and stillbirth rates has lagged behind the substantial progress in reducing postneonatal and maternal mortality rates. The benefits to prenatal an... more

Download (84)

View PDF (76)

Fight for what counts. Investment Case

The Global Fund (2022) CC

Over the 20 years that followed, this unique partnership has invested more than US$53 billion, saving 44 million lives and reducing the combined death rate from the three diseases by more than half in the countries in which the Global Fund invests.

Download (95)

View PDF (115)

Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995-2015

Global Burden of Disease Health Financing Collaborator Network Lancet (2018) CC

Background: Comparable estimates of health spending are crucial for the assessment of health systems and to optimally deploy health resources. The methods used to track health spending continue to evolve, but little is known about the distribution of spending across diseases. We developed improved e... more

Download (88)

View PDF (103)

Management and Prevention Strategies for Non-communicable Diseases (NCDs) and Their Risk Factors

Budreviciute, A.; Damiati, S.; Khdr Sabir, D. et al. (2020) CC

Non-communicable diseases (NCDs) are of increasing concern for society and national governments, as well as globally due to their high mortality rate. The main risk factors of NCDs can be classified into the categories of self-management, genetic factors, environmental factors, factors of medical co... more

Download (148)

View PDF (298)

Sanitary inspection packages – A supporting tool for the Guidelines for drinking water quality: Small water supplies

World Health Organization WHO (2024) C_WHO

A sanitary inspection is a simple, on-site evaluation (traditionally using a checklist) to help identify and support the management of priority risk factors that may lead to contamination of a drinking-water supply. Sanitary inspections are a well-established and widely-applied practice. They can su... more

Download (152)

View PDF (112)

Compendium of WHO and other UN guidance on health and environment: version with International Classification of Health Intervention (‎ICHI)‎ codes

World Health Organization WHO (2024) C_WHO

In this version of the compendium, each guidance is coded using the International Classification of Health Interventions (ICHI). The compendium provides a systematic compilation of published guidance from WHO and other UN organizations on health and environment. Guidance on policies and actions a... more

Download (200)

View PDF (140)

WHO benchmarks for strengthening health emergency capacities
recommended

World Health Organization WHO (2024) C_WHO

Benchmarking is a strategic process often used by businesses and institutes to standardize performance in relation to the best practices of their sector. The World Health Organization (WHO) and partners have developed a tool with a list of benchmarks and corresponding suggested actions that can be a... more

Download (144)

View PDF (319)

Addressing Inequalities in Global Health: UNU IIGH Strategic Plan 2024–2028

United Nations University UNU (2024) C1

The 2019-2023 Strategy for UNU-IIGH, developed in 2018, built on UNU-IIGH’s strategic advantage and position vis-à-vis the UN and global health ecosystem. The Strategy set a goal to advance evidencebased policy on key issues related to sustainable development and health and shifted the Instit... more

Download (118)

View PDF (289)

The Somali strategy for Cholera prevention and control 2020-2024
recommended

Government of SomaliaWorld Health Organization WHO (2023) C_WHO

Cholera is an acute gastrointestinal infection caused by the bacterium Vibrio Cholerae serogroup O1 or O139, and is often linked to unsafe drinking water, lack of proper sanitation and personal hygiene. It adversely affects mostly the poor and vulnerable populations in countries, which are already d... more

Download (97)

View PDF (300)

Policy options to mitigate a drop in fiscal space for health and HIV following the COVID-19 pandemic — Case studies from the Democratic Republic of the Congo, Jamaica and Lesotho, November 2020

UNAIDS (2021) CC

To assess the impact of the COVID-19 pandemic on health and HIV expenditure, UNAIDS carried out a modelling study on fiscal space for health and HIV. From a sample of 28 countries, three countries—the Democratic Republic of the Congo, Jamaica, and Lesotho—were selected to capture health and HIV ... more

Download (302)

View PDF (114)

Financing Global Health 2015: Development assistance steady on the path to new Global Goals

Institute for Health Metrics and Evaluation (2016) CC

Financing Global Health 2015 is the seventh edition of IHME’s annual series on global health financing. This report captures trends in development assistance for health (DAH) and government health expenditure as source (GHE-S) in low- and middle-income countries. Annually updated GHE-S and DAH est... more

Download (129)

View PDF (210)

Financing Global Health 2014: Shifts in Funding as the MDG Era Closes

Institute for Health Metrics and Evaluation (2015) CC

Financing Global Health 2014 is the sixth edition of this annually produced report on global health financing. As in previous years, this report captures trends in development assistance for health (DAH) and government health expenditure (GHE). Health financing is one of IHME’s core research areas... more

Download (111)

View PDF (157)

Financing Global Health 2013: Transition in an Age of Austerity

Institute for Health Metrics and Evaluation (2014) CC

Financing Global Health 2013: Transition in an Age of Austerity, IHME’s fifth annual report on global health expenditure, depicts financing trends that underline the resilience of development assistance for health. This year’s updated estimates show that despite lackluster economic growth and fi... more

Download (83)

View PDF (194)

Fully fiund the global fund: Get back on track to ende AIDS, TB and Malaria in a Covid world

Global Fund Advocates Network (2021) CC

In 2019, the Global Fund’s 6th Replenishment raised more than $USD14 billion to fight HIV, Tuberculosis and Malaria. Just two years later, the world has changed significantly. Put simply: COVID-19 devastated prevention and treatment programs. For the first time since the Global Fund’s founding, ... more

Download (117)

View PDF (104)

Finanzielle Anstrengungen für die Verwirklichung von SDG 3

Rüppel, J.; Rüppel, T. medmissio (2019) CC

MOBILISIERUNG INLÄNDISCHER ÖFFENTLICHER RESSOURCEN FÜR GESUNDHEIT

Download (126)

View PDF (97)

Donor Government Funding for HIV in Low- and Middle-Income Countries in 2022

Wexler A.; Kates J,; UNAIDS (2023) C2

This report provides an analysis of donor government funding to address the HIV response in low- and middle-income countries in 2022, the latest year available, as well as trends over time. It includes both bilateral funding from donors and their contributions to the Global Fund to Fight AIDS, Tub... more

Download (122)

View PDF (150)

Global child and adolescent mental health: The orphan of development assistance for health

Lu C., Li Z.; Patel V. PLOS Medecine (2018) CC

More than 40% of the world population is 24 years old or younger, the vast majority of whom live in low- and lower middle–income countries. Globally, a quarter of disability-adjusted life years (DALYs) for mental disorders and substance abuse is borne by this age group and about 75% of mental diso... more

Download (116)

View PDF (88)

Closing the SDG budget gap

Move Humanity (2018) CC

This report shows that increased domestic revenues can and will cover only part of the necessary SDG budget spending of the LIDCs. Achieving the SDGs in the LIDCs will also require increases of both Official Development Assistance (ODA) and Private Development Assistance (PDA) to reach aggregate lev... more

Download (247)

View PDF (333)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (128)

View PDF (130)

Pre-referral treatment with rectal artesunate of children with suspected severe malaria: a field guide

World Health Organization WHO (2023) C_WHO

Prompt, effective antimalarial treatment, and supportive care can substantially reduce the rate of mortality from severe malaria. However, many children in malaria-endemic countries do not have access to health facilities or a qualified health care provider and do not receive the necessary care in a... more

WHO benchmarks for strengthening health emergency capacities recommended

The Somali strategy for Cholera prevention and control 2020-2024 recommended

WHO benchmarks for strengthening health emergency capacities
recommended

The Somali strategy for Cholera prevention and control 2020-2024
recommended